GSK Coreg adds mortality claim
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Revised labeling for GlaxoSmithKline's Coreg (carvedilol) cites a 23% risk reduction in all-cause mortality for myocardial infarction patients. FDA approved the beta blocker March 27 for reducing cardiovascular mortality in clinically stable post-MI patients with left ventricular dysfunction. The sNDA was based on GSK's 1,959-patient CAPRICORN study, in which all-cause mortality was 15% for placebo and 12% for Coreg (p=0.03). Labeling does not mention that results did not meet the pre-specified p-value of .004 for statistical significance; FDA's Cardiovascular & Renal Drugs Advisory Committee voted Jan. 7 that other Coreg studies and experience with other beta blockers supported the indication. GSK is promoting Coreg as "the only beta-blocking agent approved to reduce the risk of death in mild, moderate and severe heart failure
You may also be interested in...
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.